Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 73.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,568 shares of the company's stock after buying an additional 6,575 shares during the quarter. Sanibel Captiva Trust Company Inc.'s holdings in Novo Nordisk A/S were worth $1,339,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James & Associates lifted its position in shares of Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company's stock worth $419,939,000 after purchasing an additional 36,223 shares during the last quarter. Natixis Advisors LLC increased its stake in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company's stock worth $366,125,000 after buying an additional 80,070 shares during the period. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC grew its stake in Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock worth $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Finally, LPL Financial LLC increased its position in shares of Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company's stock worth $162,266,000 after acquiring an additional 47,496 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE:NVO traded down $4.33 during trading on Friday, reaching $78.74. The stock had a trading volume of 21,239,835 shares, compared to its average volume of 8,206,201. The firm's 50-day simple moving average is $97.76 and its 200 day simple moving average is $117.05. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.